Synthesis and structure–activity relationship of 8-substituted protoberberine derivatives as a novel class of antitubercular agents

Ying-Hong Li†, Hai-Gen Fu†, Feng Su2, Li-Mei Gao1, Sheng Tang1, Chong-Wen Bi1, Yu-Huan Li1, Yan-Xiang Wang1* and Dan-Qing Song1*

Abstract

Background: The emergence of multi-drug resistant tuberculosis (MDR-TB) has heightened the need for new chemical classes and innovative strategies to tackle TB infections. It is urgent to discover new classes of molecules without cross-resistance with currently used antimycobacterial drugs.

Results: Eighteen new 8-substituted protoberberine derivatives were synthesized and evaluated for their anti-mycobacterial activities against Mycobacterium tuberculosis (M. tuberculosis) strain H37Rv. Among them, compound 7g was the most effective antitubercular agent with minimum inhibitory concentration (MIC) of 0.5 μg/mL. Moreover, it also afforded a potent antitubercular effect against clinically isolated MDR strains of M. tuberculosis with MICs ranging from 0.25 to 1.0 μg/mL, suggesting a novel mode of action.

Conclusions: The structure–activity relationship (SAR) analysis revealed that introduction of a substituent at the 8-position in pseudoprotoberberine, especially an n-decyl, could significantly enhance the anti-TB activity. We consider 8-n-decylberberines to be a novel family of anti-tubercular agents with an advantage of inhibiting MDR strains of M. tuberculosis.

Keywords: 8-Substituted-protoberberine, Antitubercular, Structure–activity relationship, Drug–resistance

Background

Currently, one third of the world's population is infected with Mycobacterium tuberculosis (M. tuberculosis) [1]. It is anticipated that there will be about 8.9–9.9 million new and relapse tuberculosis (TB) cases this year, more than in any other year in history [2,3]. The limited effectiveness and long-term treatment lead to poor patient compliance, which often causes multi-drug resistant (MDR) and extensively-drug-resistant (XDR). The emergence of new cases, the increased incidence of MDR strains of M. tuberculosis, the adverse effects of first-line anti-TB drugs isoniazid (INH) and rifampin (rif) [4,5], and the increased incidence of TB associated with HIV infections [6-8] have led to renewed research interest in discovering novel anti-TB drugs. Especially, the emergence of MDR-TB and of the virtually untreatable MDR-TB has heightened the need for new chemical class and innovative strategies to tackle TB infections. However, truly novel antitubercular drugs other than repurposed drugs have not been developed since the 1970s [9,10]. Though new anti-TB drug Bedaquiline was just approved by FDA last year [11], there is still an urgent need to discover new classes of molecules without cross-resistance with currently used antimycobacterial drugs.

We have identified 13-substituted protoberberine derivatives to be a novel family of anti-TB agents [12] with poor solubility. The primary structure–activity relationship (SAR) indicated that the berberine ring (BBR, I, Figure 1) might be beneficial for keeping good antitubercular activity. In our ongoing efforts to discovering new anti-TB agents, we turned our SAR analysis on the substituents at the 8-position of BBR derivatives, by which nitrogen ion at the 7-position might be blocked by the 8-substituents with bigger volume, thereby enhancing the solubility of...
this kind of compounds. Based on this strategy, several 8-substituted protoberberine derivatives (6a–e) were designed, semi-synthesized and evaluated for their antimycobacterial activity against *M. tuberculosis* strain H37Rv. Furthermore, by replacing 1 with pseudoberberine (2, Figure 1) or palmatine (3, Figure 1) core, two natural products extracted from Chinese herb Huanglian, by which a group of new 8-substituted pseudoberberine (7a–h) or palmatine (8a–e) derivatives was generated for testing. Herein, eighteen 8-substituted protoberberine derivatives (Figure 2) were designed and synthesized, and their anti-mycobacterial effects were evaluated afterwards.

**Results and discussion**

**Chemistry**

Eighteen target compounds were synthesized with commercially available 1, 3 or 2 (synthesized in our laboratory) [13,14] as the starting material as described in Scheme 1. The Grignard reagents were first prepared with Mg turnings and the corresponding alkyl and aryl iodide in absolute ether under N₂ protection. The key intermediates dihydroberberine, dihydropseudoberberine or dihydropalmatine (4) were obtained via nucleophilic substitution of newly synthesized Grignard reagents with 1, 2 or 3 under N₂ protection, respectively [15,16]. Then, the intermediate 4 was oxidized using bromine as a oxidizing agent in HOAc at refluxing temperature to yield the 8-substituted berberine bromate 5, which was converted into the corresponding chloride 6–8 with AgCl in MeOH at room temperature. Finally, the desired products in series 6, 7 and 8 were purified by flash column chromatography using methanol/dichloromethane as the gradient eluent with overall yields of 72%–81%.
Biological activity and SAR analysis of 8-substituted protoberberine derivatives for anti-mycobacterial activity

Our SAR strategy was first focused on the modifications of the substituents at the 8-position in BBR. According to our previous SAR results, several lipophilic groups including \( \text{p-methoxyphenyl} \) (6a), \( \text{m-methoxyphenyl} \) (6b), \( \text{p-methylphenyl} \) (6c), 1-naphthyl (6d) and \( \text{n-decyl} \) (6e) were introduced into the 8-position aiming to improve the cLogP value (Table 1), thereby enhancing the anti-mycobacterial activity. Among these analogues, compound 6e possessing an \( \text{n-decyl} \) afforded the highest antibacterial activity with a MIC of 2.0 \( \mu \text{g/mL} \) against \( \text{M. tuberculosis} \). The results supported that the increased cLogP value might be helpful for enhancing the anti-TB activity of this kind of compounds.

In order to further explore the influence of the BBR core, a variety of lipophilic substituents were attached to the 8-position of \( \text{2} \), by which the 8 new 8-substituted pseudoberberine classes (7a–h) were generated for testing. The results showed (Table 1) that the majority of them (7b–h) exhibited potential anti-mycobacterial activities with MICs ranging from 0.5 \( \mu \text{g/mL} \) to 2.0 \( \mu \text{g/mL} \). It seems that the 10,11-dimethoxy on the ring D would be beneficial for their binding affinity to the target molecular. Compound 7g bearing an \( \text{n-decyl} \) afforded the best anti-TB activity with a MIC of 0.5 \( \mu \text{g/mL} \). Similarly, the lipophilic side-chains were also introduced to the same position in 3, and then 5 new 8-substituted palmatine analogues (8a–e) were made. As expected, compound 8e with an \( \text{n-decyl} \) at position 8 had the most potent activity with an MIC of 1.0 \( \mu \text{g/mL} \). It was deduced that an \( \text{n-decyl} \) at the 8-position would improve the anti-mycobacterial activity as regarding to this kind of compounds. The pseudoberberine ring might be beneficial for the antimycobacterial activity, and thus the representative compounds in 7 series were chosen for further investigation.

Anti-resistance TB effect of 7g and 7f

As compound 7g bearing an \( \text{n-alkyl} \) at position 8 possessed an excellent activity against drug-susceptible \( \text{M. tuberculosis} \) strain \( \text{H}_{37}\text{Rv} \), it was selected to test the anti-TB activity against MDR strains. In this experiment, \( \text{M. tuberculosis} \) strains 87, 192, 262 and 266 isolated from the patient infected with tuberculosis in China, were resistant to both RIF and INH. RIF and INH showed a decreased activity against the drug-resistant strains partially or completely with MIC ranges between 2 and > 32 \( \mu \text{g/mL} \) (Table 2), while compound 7g afforded a potential effect against MDR strains with comparable MIC ranges of 0.25–1 \( \mu \text{g/mL} \). In addition, compound 7f possessing an aromatic moiety at the 8-position in 7 series afforded a moderate cLogP value (cLogP = 1.60) and then was chosen to evaluate for the drug-resistant strains as well. As described in Table 2, 7f showed an equivalent potency against the drug-susceptible strain \( \text{H}_{37}\text{Rv} \) and multidrug-resistance isolates of \( \text{M. tuberculosis} \) strains 257, 373, 559 and 164 with a MIC range between 2 and 4 \( \mu \text{g/mL} \) as well. The results indicated that 7g and 7f were effective for drug-resistant TB.
susceptible *M. tuberculosis* as well as MDR strains isolated from TB patients in China, suggesting a mode of action different from currently used anti-TB drugs.

Cytotoxicity of 7g and 7f in Vero and MRC-5 cells
Both of compounds 7g and 7f were further tested their cytotoxicity in African green monkey kidney (Vero) and human lung fibroblast (MRC-5) cells with MTT assay. Cytotoxicity activity was expressed with CC50 value, and the selectivity index (SI), as an important therapeutic indication, was calculated as the ratio of CC50 to MIC value. Anti-TB effect of compounds 7g and 7f was evaluated by combining their MIC with SI values. As described in Table 3, compound 7g showed a moderate SI value of 10.3 and 17.6 in Vero and MRC-5 cells, respectively.

### Table 1 SAR of 8-substituted protoberberine analogous against *M. tuberculosis* strain H37Rv

| Compd | R1 | R2 | R3 | R4 | R5 | R6 | MIC | cLogP |
|-------|----|----|----|----|----|----|-----|------|
| 1     |    |    |    |    |    |    | >128 | -0.77 |
| 2     |    |    |    |    |    |    | 128  | -1.08 |
| 3     |    |    |    |    |    |    | >128 | -0.77 |
| 6a    | PhOCH3-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 32   | 0.35 |
| 6b    | PhOCH3-m | OCH3 | OCH3 | OCH3 | OCH3 | H | 16   | 0.35 |
| 6c    | PhCH3-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 16   | 0.93 |
| 6d    | 1-naphthyl | OCH3 | OCH3 | OCH3 | OCH3 | H | 8    | 1.60 |
| 6e    | n-C10H21 | OCH3 | OCH3 | OCH3 | OCH3 | H | 2    | 3.29 |
| 7a    | PhOCH3-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 4    | 0.35 |
| 7b    | PhOCH3-m | OCH3 | OCH3 | OCH3 | OCH3 | H | 2    | 0.35 |
| 7c    | PhCH3-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 2    | 0.93 |
| 7d    | PhCl-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 1    | 1.14 |
| 7e    | PhCl-m | OCH3 | OCH3 | OCH3 | OCH3 | H | 2    | 1.14 |
| 7f    | 1-naphthyl | OCH3 | OCH3 | OCH3 | OCH3 | H | 2    | 1.60 |
| 7g    | n-C10H21 | OCH3 | OCH3 | OCH3 | OCH3 | H | 0.5  | 3.29 |
| 7h    | n-C10H21 | OCH3 | OCH3 | OCH3 | OCH3 | H | 1    | 4.35 |
| 8a    | PhOCH3-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 16   | 0.04 |
| 8b    | PhOCH3-m | OCH3 | OCH3 | OCH3 | OCH3 | H | 16   | 0.04 |
| 8c    | PhCH3-p | OCH3 | OCH3 | OCH3 | OCH3 | H | 16   | 0.62 |
| 8d    | 1-naphthyl | OCH3 | OCH3 | OCH3 | OCH3 | H | 4    | 1.29 |
| 8e    | n-C10H21 | OCH3 | OCH3 | OCH3 | OCH3 | H | 1    | 2.98 |
| RIF   | 0.0625 |     |     |     |     |     | 3.90 |
| INH   | 0.0625 |     |     |     |     |     | -1.12 |

### Table 2 In vitro antitubercular activities of compounds 7f and 7g against M. tuberculosis

| Compd | MIC(MIC: μg/mL) |
|-------|----------------|
| 7f    | 257/87 373/192 559/262 164/266 H37Rv |
| 7g    | 0.5 0.25 0.5 1 0.5 |
| RIF   | >32 >32 >32 >32 0.0625 |
| INH   | 2 4 2 2 0.0625 |

### Table 3 Cytotoxicity of compounds 7f and 7g in Vero and MRC-5 cells

| Compd | Vero | MRC-5 |
|-------|------|-------|
| 7f    | 14.72 ± 2.02 | 7.37 |
| 7g    | 5.15 ± 1.29 10.3 | 8.78 ± 0.48 17.6 |

**a**: MDR strains were isolated from patients with tuberculosis in China.  
**b**: MIC values against MDR strains 257, 373, 559 and 164.  
**c**: MIC values against MDR strains 87, 192, 262 and 266.  
**d**: Cytotoxic concentration required to inhibit Vero or MRC-5 cell growth by 50%.  
**e**: Selectivity index (SI) value equaled to CC50/MIC.

### Experimental

**Instruments**

Melting point (m.p.) was uncorrected and recorded on a Mettler Toledo MP90 melting point apparatus. 1H NMR
and 13C NMR spectra were recorded on Varian 400 MHz spectrometer. Chemical shift was reported relative to internal tetramethylsilane (δ 0.00 ppm) or (CD$_3$)$_2$SO (δ 2.50 ppm) for 1H and (CD$_3$)$_2$SO (δ 39.5 ppm) for 13C. ESI high-resolution mass spectra (HRMS) were recorded on an Autospec Ultima-TOF mass spectrometer (Micromass UK Ltd, Manchester, UK). Flash chromatography was performed on CombiflashRf 200 (Teledyne, Nebraska, USA), particle size 0.038 mm.

**General procedure to obtain final 8-substituted protoberberine derivatives**

Grignard reagents were prepared via Magnesium turnings (3.8 g) with the corresponding alkyl and aryl iodides (0.13 mol) in absolute ether (100 mL) at 0°C. The synthesized Grignard reagents were added to the suspension of dry protoberberine derivatives and the reaction. The aqueous phase was extracted with ethyl acetate (3 × 100 mL) and the combined organic layers were washed with saturated brine (100 mL) and dried (Na$_2$SO$_4$). The mixture was concentrated in vacuo to give Grignard reagents were added to the suspension of dry 1, 2 or 3 (0.03 mol) in absolute ether (100 mL) dropwise under N$_2$ protection at 0°C [15,16]. After refluxing for 2 h, saturated NH$_4$Cl solution (200 mL) was added to quench the reaction. The aqeous phase was extracted with ethyl acetate (3 × 100 mL) and the combined organic layers were washed with saturated brine (100 mL) and dried (Na$_2$SO$_4$). The mixture was concentrated in vacuo to give 4. Then, bromine solution (1N/ HOAc, 30 mL) was added to oxidize compound 4 in HOAc at refluxing temperature to generate the 8-substituted BBR derivatives bromate 5, which was treated with excessive AgCl in MeOH at room temperature thus converted into the corresponding chloride form. Finally, the desired products in series 6, 7 and 8 were purified by flash column chromatography using methanol/ dichloromethane as the gradient eluent with overall yields of 72%–81%.

**8-(p-Methoxy)phenylprotoberberine choride (6a)**

Yield: 78%; Brown solid; mp 220–221°C; 1H NMR: δ 9.04 (s, 1H), 8.23 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 9.2 Hz, 1H), 7.84 (s,1H), 7.56 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H), 7.04 (s,1H), 6.18 (s,2H), 4.26 (t, J = 6.8 Hz, 2H), 4.00 (s, 3H), 3.98 (s, 3H), 3.20 (s, 3H), 3.01(t, J = 6.8 Hz, 2H); 13C NMR: δ 172.40, 160.65, 156.96, 153.08, 150.26, 148.18, 145.55, 138.47, 133.66, 131.30, 129.73, 126.90, 126.30, 124.72, 122.84, 121.88, 121.81, 114.41, 110.01, 108.36, 106.31, 102.56, 61.09, 57.44, 55.90, 52.26, 26.67; HRMS-ESI: m/z calcd 442.16490 C$_{27}$H$_{24}$NO$_3$Cl [M – Cl]$^+$, found 442.16476.

**8-(p-Methyl)phenylprotoberberine choride (6c)**

Yield: 80%; Orange solid; mp 128–129°C; 1H NMR: δ 8.87 (s, 1H), 7.79 (s, 1H), 7.68 (s, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.70 (s,1H), 6.19 (s, 2H), 4.34 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.92 (s, 3H), 3.71 (s, 3H), 3.04 (t, J = 6.4 Hz, 2H); 13C NMR: δ 161.47, 157.40, 155.03, 152.41, 150.32, 148.17, 139.55, 136.77, 131.66, 131.56, 131.39, 123.39, 122.89, 119.24, 116.98, 115.36, 108.50, 106.94, 106.22, 106.13, 102.55, 57.23, 56.27, 55.99, 52.12, 26.82; HRMS-ESI: m/z calcd 442.16490 C$_{27}$H$_{24}$NO$_3$Cl [M – Cl]$^+$, found 442.16488.
8-(m-Methoxy)phenylpseudoprotoberberine chloride (7b)
Yield: 77%; Yellow solid; mp 224−225°C; 1H NMR: δ 8.90 (s, 1H), 7.80 (s, 1H), 7.67−7.71 (m, 2H), 7.30−7.35 (m, 2H), 7.26 (d, J = 6.4 Hz, 1H), 7.08 (s, 1H), 6.66 (s, 1H), 6.19 (s, 2H), 4.33 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.85 (s, 3H), 3.70 (s, 3H), 3.06 (t, J = 6.4 Hz, 2H); 13C NMR: δ 160.14, 157.53, 154.44, 152.48, 152.40, 148.20, 139.48, 134.92, 132.26, 131.74, 131.34, 122.93, 121.79, 121.62, 119.33, 117.31, 115.15, 108.54, 106.72, 106.20, 106.08, 105.27, 57.25, 56.27, 55.99, 52.27, 26.78; HRMS-ESI: m/z calcd 442.16490 C27H24NO4Cl [M − Cl]⁺, found 442.16475.

8-(p-Methyl)phenylpseudoprotoberberine chloride (7c)
Yield: 78%; Yellow solid; mp 212−213°C; 1H NMR: δ 8.89 (s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 7.61 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.65 (s, 1H), 6.19 (s, 2H), 4.31 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.69 (s, 3H), 3.05 (t, J = 6.4 Hz, 2H), 2.54 (s, 3H); 13C NMR: δ 157.44, 155.01, 152.43, 150.34, 146.65, 148.18, 141.42, 139.55, 136.85, 131.35, 130.50, 129.66, 128.20, 121.33, 121.87, 119.30, 108.51, 106.80, 106.21, 106.14, 102.56, 57.24, 56.25, 52.20, 26.78, 21.64, 21.52; HRMS-ESI: m/z calcd 426.16998 C26H22NO4Cl [M − Cl]⁺, found 426.16986.

8-(p-Chloro)phenylpseudoprotoberberine chloride (7d)
Yield: 75%; Bright yellow solid; mp 183−184°C; 1H NMR: δ 8.91 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.87 (d, J = 8.0 Hz, 2H), 7.75−7.80 (m, 1H) 7.69 (s, 1H), 7.08 (s,1H), 6.60 (s, 1H), 6.19 (s, 2H), 4.30 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.72 (s, 3H), 3.06 (t, J = 6.4 Hz, 2H); 13C NMR: δ 157.55, 153.59, 152.59, 150.41, 148.22, 139.64, 136.97, 134.87, 132.64, 131.83, 130.97, 130.20, 128.99, 125.60, 123.05, 121.76, 119.55, 108.56, 106.50, 106.22, 105.06, 102.60, 57.28, 56.39, 52.38, 26.76; HRMS-ESI: m/z calcd 446.11536 C26H19NO4Cl2 [M − Cl]⁺, found 446.11483.

8-(m-Chloro)phenylpseudoprotoberberine chloride (7e)
Yield: 76%; Bright yellow solid; mp 179−180°C; 1H NMR: δ 8.85 (s, 1H), 7.79−7.90 (m, 5H), 7.71 (s, 1H), 7.08 (s, 1H), 6.57 (s, 1H), 6.20 (s, 2H), 4.32 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.71 (s, 3H), 3.07 (t, J = 6.4 Hz, 2H); 13C NMR: δ 157.58, 152.94, 152.63, 150.44, 148.23, 139.58, 137.05, 134.69, 132.96, 131.98, 131.74, 131.35, 129.59, 128.64, 123.00, 121.69, 119.63, 108.57, 106.40, 106.23, 106.14, 102.61, 57.31, 56.36, 52.46, 26.76; HRMS-ESI: m/z calcd 446.11536 C26H21NO4Cl2 [M − Cl]⁺, found 446.11481.

8-(1-Naphthyl)pseudoprotoberberine chloride (7f)
Yield: 72%; Yellow-brown solid; mp 198−200°C (decomp); 1H NMR: δ 9.14 (s, 1H), 8.38 (d, J = 7.8 Hz, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.84−7.92 (m, 4H), 7.67−7.71 (m, 1H), 7.51−7.55 (m, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.05 (s, 1H), 6.34 (s, 1H), 6.20 (s, 2H), 4.20−4.32 (m, 2H), 4.10 (s, 3H), 3.43 (s, 3H), 2.93−3.05 (m, 2H); 13C NMR: δ 157.14, 152.66, 152.16, 149.89, 147.72, 139.79, 136.83, 133.09, 131.62, 130.90, 130.17, 129.01, 128.92, 128.36, 127.50, 127.35, 125.86, 124.42, 123.19, 121.54, 119.55, 108.07, 105.90, 105.80, 105.65, 102.12, 56.85, 55.65, 55.15, 26.40; HRMS-ESI: m/z calcd 462.17053 C30H22NO4Cl [M − Cl]⁺, found 462.17072 (See Additional file 1).
6.4 Hz, 2H); 13C NMR: δ 165.70, 159.62, 156.25, 152.87, 152.04, 149.24, 145.37, 138.59, 136.24, 133.82, 130.42, 129.30, 126.42, 124.54, 122.36, 121.50, 120.10, 115.78, 113.73, 111.21, 109.66, 61.13, 57.42, 56.73, 56.34, 55.87, 52.49, 26.35; HRMS-ESI: m/z calcld 458.19619 C_{28}H_{28}NO_{5}Cl [M – Cl]^{+}, found 458.19615.

8-(p-Methyl)phenylprotopalmitine choride (8c)

Yield: 74%; Yellow-brown solid; mp 177–178°C; 1H NMR: δ 9.34 (s, 1H), 8.20–8.25 (m, 3H), 8.18 (d, J = 8.4 Hz, 1H), 7.74 (s, 1H), 7.76–7.80 (m, 2H), 7.63–7.67 (m, 1H), 7.47–7.49 (m, 2H), 7.02 (s, 1H), 4.13–4.35 (m, 2H), 3.99 (s, 3H), 3.94 (s, 3H), 3.85 (s, 3H), 2.93–3.05 (m, 2H), 2.77 (s, 3H); 13C NMR: δ 172.49, 156.94, 152.89, 152.01, 149.22, 145.44, 139.80, 138.66, 133.78, 132.22, 129.51, 129.29, 128.00, 127.93, 126.38, 124.57, 122.56, 121.47, 120.70, 111.19, 109.67, 61.02, 57.43, 56.74, 56.34, 52.45, 26.32, 21.59; HRMS-ESI: m/z calcld 442.20128 C_{28}H_{28}NO_{4}Cl [M – Cl]^{+}, found 442.20128.

8-(1-Naphthyl)protopalmitine choride (8d)

Yield: 78%; Yellow-brown solid; mp 164–165°C; 1H NMR: δ 9.15 (s, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.15 (d, J = 9.2 Hz, 1H), 7.76 (s, 1H), 7.46–7.52 (m, 4H), 7.04 (s, 1H), 4.25 (t, J = 6.4 Hz, 2H), 4.00 (s, 3H), 3.96 (s, 3H), 3.86 (s, 3H), 3.18 (s, 3H), 3.03 (t, J = 6.4 Hz, 2H), 2.48 (s, 3H); 13C NMR: δ 165.80, 159.64, 156.25, 152.87, 152.04, 149.24, 145.37, 138.59, 136.24, 133.82, 130.42, 129.30, 126.42, 124.54, 122.36, 121.50, 120.10, 115.78, 113.73, 111.21, 109.66, 61.13, 57.42, 56.73, 56.34, 55.87, 52.49, 26.35; HRMS-ESI: m/z calcld 492.31084 C_{31}H_{42}NO_{4}Cl [M – Cl]^{+}, found 492.31064.

8-(n-Decyl)protopalmitine choride (8e)

Yield: 75%; Brown solid; mp 172–173°C; 1H NMR: δ 8.90 (s, 1H), 8.20 (d, J = 9.2 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.65 (s, 1H), 7.13 (s, 1H), 4.83 (t, J = 6.4 Hz, 2H), 4.07 (s, 3H), 4.05 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 3.18 (t, J = 6.4 Hz, 2H), 1.79 (t, J = 6.4 Hz, 2H), 1.27–1.60 (m, 16H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR: δ 176.25, 161.55, 152.84, 151.86, 149.18, 146.05, 138.49, 133.20, 129.31, 125.67, 125.08, 121.62, 120.35, 111.06, 109.62, 62.04, 57.50, 56.68, 56.36, 50.23, 32.77, 31.78, 29.84, 29.48, 29.46, 29.23, 29.19, 28.43, 26.84, 22.58, 14.45; HRMS-ESI: m/z calcld 492.31084 C_{31}H_{42}NO_{4}Cl [M – Cl]^{+}, found 492.31064.

Biological activity assay

18 newly synthesized analogues were evaluated for their activity against the multiplication of wild-type M. tuberculosis strain H37Rv and MRD strains by the microplate alamar blue assay (MABA) at various concentrations of 128.0, 64.0, 32.0, 16.0, 8.0, 4.0, 2.0, 1.0, 0.5, 0.25, 0.125, and 0.0625 μg/ml. RIF and INH were used as positive controls. Subsequent two-fold dilutions were performed in 100 μL of 7H9 media in the 48-well microplates. Then 100 μL of bacterial suspension was added to result in a final bacterial titer of 1 × 10^6 CFU/mL. Plates were incubated at 37°C. At optimal time, alamar blue solution was added to the entire plate. Results were recorded at 24 h post-reagent addition. Visual MIC value was defined as the lowest concentration of drug that prevented a color change.

Cytotoxicity activity assay

African green monkey kidney (Vero) cells (6 × 10^3 cells/well) and human lung fibroblast (MRC-5) cells (1.2 × 10^4 cells/well) were plated into a 96-well plates and incubated at 37°C in 5% CO_2. Sixteen hours later the cell cultures were treated with various concentrations of compounds 7f and 7g. Cytotoxicity was evaluated with the tetrazolium 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at 48 h. The 50% cytotoxic concentration (CC_{50}) was calculated with Reed & Muench methods. Each experiment was repeated three times.

Conclusion

In conclusion, 18 new 8-substituted BBR derivatives were synthesized and evaluated for their antimycobacterial activities against M. tuberculosis H37Rv. SAR analysis revealed that (i) introduction of a n-decyl at the 8-position might significantly enhance the activity; (ii) 10,11-dimethoxy on the ring D might be beneficial for the antimycobacterial activity. Among the test compounds, compound 7g exhibited the strongest activity against both drug-susceptible strains and MDR isolates of M. tuberculosis, suggesting a novel mechanism of action. It has been selected as an ideal compound lead against TB for further SAR investigation. We consider 8-n-decylderberines to be a novel family of anti-tubercular agents with an advantage of inhibiting MDR strains of M. tuberculosis.

Additional file

Additional file 1: Supporting information. Selected copies of spectrum (1H-NMR, 13C-NMR and HRMS) for the two representative compounds.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

The current study is an outcome of the constructive discussion with DQS and YWW, who offered necessary guidance to YHL and HGF to carry out their synthesis and characterization experiments. FS and LMG performed the antimycobacterial activities against M. tuberculosis H37Rv tests, ST and CWB carried out the 1H NMR and 13C NMR spectral analyses and HRMS analysis, and YHL did the cytotoxicity experiment. All authors read and approved the final manuscript.
Acknowledgment
This work was supported by the National Natural Science Fundation for Young Scientists (81102312) and the “National Mega-project for Innovative Drugs” (2012ZX09301002–001–017).

Author details
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. 2College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.

Received: 1 April 2013 Accepted: 28 June 2013 Published: 10 July 2013

References
1. Butler D: New fronts in an old war. Nature 2000, 406:670–672.
2. Dye C, Williams BG: The population dynamics and control of tuberculosis. Science 2010, 328:865–861.
3. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K: The challenge of new drug discovery for tuberculosis. Nature 2011, 469:483–490.
4. Jiao WW, Mokrousov I, Sun GZ, Li M, Liu JW, Naruskaya O, et al: Molecular characteristics of rifampin and isoniazid resistant mycobacterium tuberculosis strains from beijing. China. Chin Med J (Engl) 2007, 120:814–819.
5. Zhao Y, Xu S, Wang L, Chin D, Wang S, Jiang G, et al: National survey of drug-resistant tuberculosis in china. N Engl J Med 2012, 366:2161–2170.
6. Verma SC, Dhungana GP, Joshi HS, Kunwar HB, Pokhrel AK: Prevalence of pulmonary tuberculosis among HIV infected persons in pokhara, nepal. J Nepal Health Res Counc 2012, 10:32–36.
7. Cain KP, Varma Jr: Finding tuberculosis at the first encounter with HIV care: don’t miss the opportunity to save a life. Int J Tuberc Lung Dis 2012, 16:1138.
8. He JL, Xie JP: Advances in mycobacterium siderophore-based drug discovery. Acta Pharmaceutica Sinica B 2011, 1:8–13.
9. Tomioka H: Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006, 12:4047–4070.
10. Spigelman MK: New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007, 196(Suppl 1):S28–34.
11. FDA: FDA news release; 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm.
12. Liu YX, Xiao CL, Wang YX, Li YH, Yang YH, Li YB, et al: Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives. Eur J Med Chem 2012, 52:151–158.
13. Yang Y, Ye XL, Li YH, Kong WI, Wang YX, Gao LM, et al: Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Bioorg Med Chem Lett 2009, 19:6004–6008.
14. Wang YX, Wang YP, Zhang H, Kong WJ, Li YH, Liu F, et al: Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg Med Chem Lett 2009, 19:6004–6008.
15. Iwasa K, Lee DU, Kang SI, Wiegrebe W: Antimicrobial activity of 8-alkyl- and 8-phenyl-substituted berberines and their 12-bromo derivatives. J Nat Prod 1998, 61:1150–1153.

doi:10.1186/1752-153X-7-117
Cite this article as: Li et al.: Synthesis and structure–activity relationship of 8-substituted protoberberine derivatives as a novel class of antitubercular agents. Chemistry Central Journal 2013 7:117.